TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations Safety continues to be a notable hallmark of TUS-based therapies 100% response rate (CR/CRh) at the two higher dose levels (80 and 120 mg TUS dose) CR/CRh observed in FLT3 wildtype subjects, representing ~70% of […]